Plus   Neg

Stock Alert: Youdao Touches New High

Shares of e-learning company Youdao, Inc. (DAO), a unit of Chinese internet company NetEase, continued to build on the momentum on Friday, surging $4.77 or 29.12% to touch a new high of $21.17, before closing at $21.15.

The stock is up more than 50% from the open price of $13.50 on October 25, 2019, its debut on the New York Stock Exchange. Trading volume was much higher on Friday at 1.4 million from the average volume of 71K.

In November last year, when Youdao reported third-quarter results, revenue increased 98.4% year-over-year to RMB345.9 million ($48.4 million), helped by 139.8% increase in gross billings from online courses.

Net loss for the quarter was RMB 242.2 million (US$33.9 million), compared with net loss of RMB77.0 million for the same period of last year. Net loss per ADS was RMB2.63 (US$0.37), compared with loss per ADS of RMB0.84 for the third quarter of 2018. Adjusted earnings per ADS jumped to RMB2.60 (US$0.36), from RMB0.82 for the third quarter of 2018.

For comments and feedback contact: editorial@rttnews.com

Business News

Editors Pick
Guitar Center Inc., a retailer of musical instruments, lessons, repairs and rentals, has filed for Chapter 11 bankruptcy reorganization, aiming to significantly reduce its debt and continue its business amid ongoing struggles following the coronavirus pandemic. The company, which operates nearly 300 stores across the U.S., expects to complete the process before the end of this year. Amazon is offering new "Spoiler Free" ways to keep gifts a surprise, as well as to track, receive and pick up orders this holiday season. According to the company, the new features would help customers to face the challenge of keeping those special gifts under wraps as many families are opting to stay home amid the coronavirus pandemic. AstraZeneca Plc and Oxford University's coronavirus vaccine candidate AZD1222 is found to be 70 percent effective on average against Covid-19, according to the British pharmaceutical giant. AstraZeneca plans to immediately prepare regulatory submission of the data to worldwide authorities for conditional or early approval. The company will also ask for an Emergency Use Listing from the WHO.
Follow RTT